Infinimmune is a biotechnology company that develops human-derived antibody medicines. Its platform combines human B-cell sequencing, antibody libraries, computational modeling, and laboratory validation to discover and engineer antibody candidates. The company develops therapeutic programs targeting conditions including atopic dermatitis, immunoglobulin A nephropathy, and ulcerative colitis. Its technologies include Complete Human sequencing, Anthrobody, and the GLIMPSE antibody language model.